Outcomes
The primary outcome was the rate of patients with a DAS28-CRP of 3.2 or less at month 6, as assessed by a rheumatologist. Secondary outcomes were also evaluated by the rheumatologist, and included the proportion of patients with moderate-to-good EULAR response rate,